Immunotech Laboraties Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status
08 4월 2013 - 10:53PM
Marketwired
Immunotech Laboratories, Inc. (PINKSHEETS:
IMMB) today announced the company signed an agreement with The
Lebrecht Group, a professional law corporation, to provide legal
services for Immunotech and to upgrade the company to OTC:BB fully
reporting current status.
Immunotech Founder, President & Chief Scientific Officer
Harry Zhabilov today commented, "This step will help assure our
investors and shareholders of the forward progression of Immunotech
in both the Medical and Investment communities."
This information is filed on the www.sec.gov website as an
official 8K filing.
Further information about Immunotech's patented "IPF" can be
obtained from www.immunotechlab.com
This news release contains forward-looking statements that
involve risks and uncertainties associated with financial
projections, budgets, milestone timelines, clinical development,
regulatory approvals, and other risks described by Immunotech
Laboratories, Inc. from time to time in its periodic reports filed
with the SEC. IPF is not approved by the US Food and Drug
Administration or by any comparable regulatory agencies elsewhere
in the world. While Immunotech Laboratories believes that the
forward-looking statements and underlying assumptions contained
therein are reasonable, any of the assumptions could be inaccurate,
including, but not limited to, the ability of Immunotech
Laboratories to establish the efficacy of IPF in the treatment of
any disease or health condition, the development of studies and
strategies leading to commercialization of IPF in the United
States, the obtaining of funding required to carry out the
development plan, the completion of studies and tests on time or at
all, and the successful outcome of such studies or tests.
Therefore, there can be no assurance that the forward-looking
statements included in this release will prove to be accurate. In
light of the significant uncertainties inherent in the
forward-looking statements included herein, Immunotech Laboratories
or any other person that the objectives and plans of Immunotech
Laboratories will be achieved should not regard the forward-looking
statements as a representation.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Company Contact: Immunotech Laboratories, Inc. Email Contact
Public Relations The Nabors Group: 713-875-9200 E-mail: Email
Contact www.facebook.com/Naborsgroup
Immunotech Laborator (CE) (USOTC:IMMB)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Immunotech Laborator (CE) (USOTC:IMMB)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Immunotech Laborator (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Immunotech Laboratories, Inc. News Articles